Skip to content
PeptidesEncyclopedia
For research use only

Not for human consumption. Consult a licensed professional.

Research chemical — not approvedaka DAC:GRF, Modified GRF (1-29) with DAC

CJC-1295 — Complete Research Guide (2026)

Last updated 2026-06-25

TL;DR

A long-acting growth-hormone-releasing hormone analog. The DAC variant was studied in early human pharmacokinetic trials.

What is CJC-1295?

CJC-1295 is a synthetic long-acting analog of growth-hormone-releasing hormone (GHRH); the version studied in humans carries a Drug Affinity Complex (DAC) that binds serum albumin, giving a multi-day half-life (estimated 5.8-8.1 days in the pivotal trial).

Human evidence is very limited, resting mainly on a small early-phase pharmacokinetic/safety study plus one related pulsatility study, supplemented by animal work; it is not approved by the FDA for any indication.

It is presented here for research and educational purposes only and is not a legitimate therapeutic or performance product.

How does CJC-1295 work?

CJC-1295 activates pituitary GHRH receptors to drive GH release, and its albumin-binding DAC modification extends exposure so a single dose can elevate GH and IGF-1 for several days.

Even under this sustained stimulation, GH is still released in pulses rather than continuously, with the main effect being raised trough GH and IGF-1. [INFOGRAPHIC: Albumin-bound long-acting GHRH analog action]

What does the research say about CJC-1295?

  • A single subcutaneous dose in healthy adults produced dose-dependent GH increases of roughly 2- to 10-fold and IGF-1 increases of about 1.5- to 3-fold lasting up to ~11 days, with no serious adverse reactions reported. [1]
  • During continuous GHRH stimulation, GH secretion remained pulsatile in healthy men while trough GH rose markedly and IGF-1 increased ~45%. [2]
  • In GHRH-knockout mice, once-daily CJC-1295 normalized body weight, length, and body composition, confirming durable GHRH-receptor activation in vivo. [4]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

  • [1] Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults — Teichman SL et al., J Clin Endocrinol Metab 2006. (phase 1 RCT (healthy adults))
  • [2] Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog — Ionescu M et al., J Clin Endocrinol Metab 2006. (human study (healthy men))
  • [3] Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects — Sackmann-Sala L et al., Growth Horm IGF Res 2009. (human serum proteomic analysis)
  • [4] Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse — Alba M et al., Am J Physiol Endocrinol Metab 2006. (animal (GHRH-knockout mice))
  • [5] An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma — Timms M et al., Drug Test Anal 2019. (analytical / anti-doping method (equine))

Dosing context

This is not medical advice or a usage recommendation. Dosing figures are reported research context only, cited from the published literature.

The published human trial administered weight-based subcutaneous doses (on the order of 30-60 microgram/kg) given weekly or biweekly under investigator supervision, reflecting its multi-day half-life.

These are descriptions of study conditions, not dosing recommendations; CJC-1295 is presented strictly as a research compound.

Side effects & safety profile

Human safety data come from only small, short early-phase trials, in which no serious adverse reactions were reported at the doses tested, so the safety profile is not well characterized.

The long, albumin-bound duration of action means GH and IGF-1 stay elevated for days after a dose, which is difficult to titrate or reverse and is a theoretical concern for sustained IGF-1 exposure.

CJC-1295 is not FDA-approved, is sold only as a research chemical or via compounding, and much online material about it is not backed by peer-reviewed human data.

Stacking & combinations

In research and non-clinical settings CJC-1295 is often discussed alongside ghrelin-receptor agonists (e.g., GHRP-6 or ipamorelin) to combine GHRH and GH-secretagogue pathways, but such combinations have no validated human safety or efficacy evidence.

Finding CJC-1295 vendors

Finding CJC-1295 vendors

This is an independent, neutral directory — we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.

Choose your country

We never list placeholder vendors. Pick your country to see neutral regulatory context.

Browse the directory

User reviews

No reviews yet

Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews — we never fabricate ratings.

Sign in to review

Frequently asked questions

No. It is not FDA-approved for any indication and is sold only as a research chemical or through compounding.

References

  1. [1] Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults — Teichman SL et al., J Clin Endocrinol Metab 2006. PMID: 16352683. View sourceStudy: phase 1 RCT (healthy adults)Single SC doses raised GH 2-10x and IGF-1 1.5-3x for days (half-life 5.8-8.1 d) with no serious adverse reactions.
  2. [2] Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog — Ionescu M et al., J Clin Endocrinol Metab 2006. PMID: 17018654. View sourceStudy: human study (healthy men)GH remained pulsatile under continuous stimulation while trough GH rose ~7.5-fold and IGF-1 ~45%.
  3. [3] Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects — Sackmann-Sala L et al., Growth Horm IGF Res 2009. PMID: 19386527. View sourceStudy: human serum proteomic analysisCJC-1295 shifted several serum proteins, some correlating with IGF-1 levels, as candidate biomarkers.
  4. [4] Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse — Alba M et al., Am J Physiol Endocrinol Metab 2006. PMID: 16822960. View sourceStudy: animal (GHRH-knockout mice)Once-daily CJC-1295 normalized growth and body composition; less frequent dosing was less effective.
  5. [5] An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma — Timms M et al., Drug Test Anal 2019. PMID: 30489688. View sourceStudy: analytical / anti-doping method (equine)Validated a sensitive immuno-PCR assay to detect CJC-1295, reflecting its status as a doping agent of concern.

Related peptides

IpamorelinGrowth HormoneMod GRF (1-29)Growth HormoneSermorelinGrowth Hormone
This article is for educational and research purposes only. Peptides discussed here are not approved for human consumption by the FDA, EMA, or equivalent regulators outside of specific clinical contexts. Always consult a licensed medical professional before any therapeutic use.